Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (May 2021)
19 slides from Cns Pharmaceuticals's investor presentation, May 18, 2021
Slide 1: www.cnspharma.com 2100 West Loop South, Suite Houston, TX 77027 (800) 946 - 9185 MAY
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP MAY 2021
Slide 2: Forward-Looking Statements
CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future results of o
Slide 3: Investment Highlights
CNS pharmaceuticals 3 Investment Highlights • Developing anti - cancer drug candidates for the treatment of primary and metastatic brain and CNS cancer • Two lead programs initially developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Cente
Slide 4: Oncology Pipeline
CNS pharmaceuticals 4 Oncology Pipeline PRODUCT SPONSOR INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 Berubicin CNS GBM (U.S., adults) Berubicin WPD GBM (Poland, adults) Q2 2021 Berubicin WPD GBM (Poland, pediatric) 2H 2021 Berubicin CNS CNS Lymphoma, Metastatic Lung & Breast 2021 - 2022 WP1244 CN
Slide 5: Management Team
CNS pharmaceuticals 5 Distinctive record of business successes and more than 15 years of experience managing the operations, strategies and finances of public and private companies. PRESIDENT & CHIEF EXECUTIVE OFFICER John M. Climaco, Esq Board certified hematologist/medical oncologist with extensiv
Slide 6: Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and
CNS pharmaceuticals 6 Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and Drug Carriers in the Department of Bioimmunotherapy at The University of Texas MD Anderson Cancer Center. Dr. Priebe is the inventor of more than 50 patents and the author of more than 200 scie
Slide 7: Glioblastoma Multiforme (GBM)
CNS pharmaceuticals 7 Glioblastoma Multiforme (GBM) 1: https://braintumor.org/take - action/about - gbm/ One of the most aggressive, deadly and treatment - resistant cancers that forms in the brain Current standard of care ineffective in ~60% of patients 12 - 18 months: Average life expectancy 1 Can
Slide 8: Lead Compound: Berubicin
CNS pharmaceuticals 8 x 44% OF PHASE 1 PATIENTS OBTAINED CLINICAL BENEFIT OF STABLE DISEASE OR BETTER x ONE COMPLETE RESPONDER FROM PHASE 1 REMAINS CANCER - FREE APPROXIMATELY 14 YEARS FOLLOWING TREATMENT • Entering potentially pivotal study for the treatment of glioblastoma in Q2 2021 • Entering tw
Slide 9: Berubicin for the Treatment of GBM: Mechanism of Action
CNS pharmaceuticals 9 based on limited clinical data, we believe BERUBICIN IS THE FIRST ANTHRACYCLINE THAT APPEARS TO CROSS THE BLOOD - BRAIN BARRIER AND IS DESIGNED TO CONCENTRATE IN TUMOR TISSUE WITHIN THE BRAIN Berubicin for the Treatment of GBM Mechanism of Action Selective update in tumor tissu
Slide 10: Demonstrated Clinical Response in GBM
CNS pharmaceuticals 10 Demonstrated Clinical Response in GBM * This does not always mean the cancer is cured. Also called a complete remission: www.cancer.gov/publications/dictionaries/cancer - terms/def/complete - response 6 MO. POST - TREATMENT Berubicin Phase 1 Results PRE - TREATMENT • 44% subje
Slide 11: Potentially Pivotal Study
CNS pharmaceuticals 11 Potentially Pivotal Study • Dose Berubicin 7.1 mg/m2 IV infusion vs. Lomustine 130 mg/m2 oral • Clinical Sites ~60 centers across; North America, Europe and Asia Pacific • Primary Endpoint Overall Survival (OS) • Secondary Endpoints Duration of Response (DoR); Objective Respon
Slide 12: Open Label Phase 2 Study in Poland
CNS pharmaceuticals 12 Open Label Phase 2 Study in Poland Adult Study Expected to Commence Q2 2021 FULLY GRANT FUNDED ($6M) AT NO COST TO CNS PHARMA CONDUCTED BY EUROPEAN PARTNER, WPD PHARMACEUTICALS • Dose Berubicin 7.1 mg/m2 IV infusion • Primary Endpoint Overall Survival (OS) • Secondary Endpoint
Slide 13: Expansion Into Other Cancers
CNS pharmaceuticals 13 Expansion Into Other Cancers INDICATION PATIENT POPULATION ESTIMATED SIZE COMMENTS Primary Brain Tumors Relapsed High Grade Gliomas 15,000 Existing data in this population Brain Metastases - Combination with Radiation Therapy Small Cell Lung Cancer 56,500 Anthracycline sensiti
Slide 14: WP1244
CNS pharmaceuticals 14 WP1244 TECHNOLOGY ORIGINALLY DEVELOPED AND LICENSED FROM THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER • Believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation • Target Indications: • Brain cancers • Pancreatic • Ovarian • Lymphomas • Tech
Slide 15: Corporate Overview
CNS pharmaceuticals 15 Corporate Overview
Slide 16: Financial Snapshot
CNS pharmaceuticals 16 Financial Snapshot Market Cap 1 ~$46M 1. As of May 16, 2021 NASDAQ: CNSP IPO $9.8M November 7, 2019 Shares Outstanding ~25.4M Average Volume 1 ~318K Cash Balance $11M As of March 31, 2020
Slide 17: Value Driving Milestones
CNS pharmaceuticals 17 Value Driving Milestones x Orphan Drug Designation June 2020 x IND Accepted for Berubicin Dec. 2020 • Initiate Potentially Pivotal US Berubicin trial for GBM Q2 2021 • WPD initiates clinical trials in Poland Adults: Phase 2 Q2 2021 Pediatrics: Phase 1 2H 2021 • Interim data fr
Slide 18: Investment Summary
CNS pharmaceuticals 18 Investment Summary DEVELOPING A PIPELINE OF ANTI - CANCER DRUG CANDIDATES FOR THE TREATMENT OF BRAIN CANCERS, AN AREA IN NEED OF NEW INNOVATIONS Multiple value - driving milestones expected throughout 2021 1 Lead program, Berubicin entering 3 clinical trials in 2021, including
Slide 19: www.cnspharma.com 2100 West Loop South, Suite Houston, TX 77027 (800) 946 - 9185
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP
CNS Pharmaceuticals — Investor Presentation (May 2021) on 6ix